From the Journals

DOACs’ safety affirmed in real-world setting


 

FROM THE BMJ

The study was supported by a grant from the National Institute for Health Research. The investigators had no relevant disclosures.

SOURCE: Vinogradova Y et al. BMJ 2018; 362:K2505.

Pages

Recommended Reading

MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Family Medicine
Impaired kidney function no problem for dabigatran reversal
MDedge Family Medicine
Does warfarin cause acute kidney injury?
MDedge Family Medicine
First reversal agent for apixaban and rivaroxaban gets fast-track approval
MDedge Family Medicine
Design limitations may have compromised DVT intervention trial
MDedge Family Medicine
DOAC’s edge over warfarin fades with low adherence
MDedge Family Medicine
Low vitamin D linked with DVT in lupus patients
MDedge Family Medicine
Canakinumab cut gout attacks in CANTOS
MDedge Family Medicine
New look at ATLAS suggests rivaroxaban may still have role in ACS
MDedge Family Medicine
DOJ lawsuit reins in inappropriate ICD use
MDedge Family Medicine